• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Role of Cdk5/ERK pathway in the pathogenesis of diabetic retinopathy

Research Project

Project/Area Number 22K09814
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56060:Ophthalmology-related
Research InstitutionThe University of Tokushima

Principal Investigator

MITAMURA Yoshinori  徳島大学, 大学院医歯薬学研究部(医学域), 教授 (30287536)

Co-Investigator(Kenkyū-buntansha) 仙波 賢太郎  徳島大学, 病院, 助教 (10745748)
江川 麻理子  徳島大学, 病院, 講師 (70507657)
Project Period (FY) 2022-04-01 – 2025-03-31
Project Status Completed (Fiscal Year 2024)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2024: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2023: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2022: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords外科 / 細胞・組織 / 生体分子 / 糖尿病 / 臨床
Outline of Research at the Start

現在に至るまで増殖糖尿病網膜症などの増殖性疾患の眼内でのCdk5とERK活性は不明である。今回、硝子体手術時に得られた臨床検体サンプルを用いてPPARγ濃度、Cdk5、ERKの眼内での活性を検索するとともに、in vitroおよびin vivoでのCdk5、ERKの血管新生促進効果を確認し、Cdk5/ERK回路によるPPARγの調節機構と糖尿病網膜症の関連について検討し、将来的にCdk5またはERK/MEK阻害剤を投与することで増殖糖尿病網膜症の進行を抑制する治療薬としての可能性を探求する。

Outline of Final Research Achievements

Cyclin-dependent kinase 5 (Cdk5) and extracellular signal-regulated kinase (ERK) are expressed in almost all organs and tissues and are known to play multiple roles, including cell proliferation. However, the activity of Cdk5 and ERK in the eyeball of patients with intraocular proliferative diseases such as proliferative diabetic retinopathy remains unclear. Therefore, we investigated the intraocular concentration of PPARγ and the activity of Cdk5 and ERK using clinical specimen samples obtained during vitreous surgery, and confirmed that the expression of PPARγ and the activation of Cdk5 and ERK were observed in the intraocular fluid (vitreous) and the proliferative membrane formed on the surface of retina in the patients with proliferative diabetic retinopathy. These findings suggest that the Cdk5/ERK signaling pathway may be involved in the pathogenesis of diabetic retinopathy.

Academic Significance and Societal Importance of the Research Achievements

以前は我が国においても糖尿病網膜症が失明原因の第一位を占めていたが、近年の薬物療法や手術治療の目覚ましい進歩により現在は失明原因の第三位となっている。しかし、糖尿病網膜症で著しい視力障害をきたし日常生活や就労に支障をきたす人が後を絶たないのが現実である。今回、我々は硝子体手術時に得られた臨床検体サンプルを用いて、増殖糖尿病網膜症の眼内でPPARγ濃度が上昇しCdk5、ERKが活性化していることを見出し、Cdk5/ERK回路が糖尿病網膜症の病因に関与している可能性が示唆された。このことはCdk5/ERK回路を標的とした糖尿病網膜症の新たな治療法と失明の予防の可能性を示すことができたと考えられる。

Report

(4 results)
  • 2024 Annual Research Report   Final Research Report ( PDF )
  • 2023 Research-status Report
  • 2022 Research-status Report
  • Research Products

    (2 results)

All 2023 2021

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results)

  • [Journal Article] Estimation of Visual Function Using Deep Learning From Ultra-Widefield Fundus Images of Eyes With Retinitis Pigmentosa2023

    • Author(s)
      Nagasato Daisuke、Sogawa Takahiro、Tanabe Mao、Tabuchi Hitoshi、Numa Shogo、Oishi Akio、Ohashi Ikeda Hanako、Tsujikawa Akitaka、Maeda Tadao、Takahashi Masayo、Ito Nana、Miura Gen、Shinohara Terumi、Egawa Mariko、Mitamura Yoshinori
    • Journal Title

      JAMA Ophthalmology

      Volume: 141 Issue: 4 Pages: 305-305

    • DOI

      10.1001/jamaophthalmol.2022.6393

    • Related Report
      2023 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Ocular expression of cyclin-dependent kinase 5 in patients with proliferative diabetic retinopathy.2021

    • Author(s)
      Hiroki Sano, Kazuhiko Namekata, Masanori Niki, Kentaro Semba, Fumiko Murao, Takayuki Harada, Yoshinori Mitamura
    • Journal Title

      Journal of Diabetes Investigation

      Volume: 13 Issue: 4 Pages: 628-628

    • DOI

      10.1111/jdi.13702

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2022-04-19   Modified: 2026-01-16  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi